ECSP12012314A - Factor viii conjugado para coagulación de la sangre - Google Patents

Factor viii conjugado para coagulación de la sangre

Info

Publication number
ECSP12012314A
ECSP12012314A ECSP12012314A ECSP12012314A EC SP12012314 A ECSP12012314 A EC SP12012314A EC SP12012314 A ECSP12012314 A EC SP12012314A EC SP12012314 A ECSP12012314 A EC SP12012314A
Authority
EC
Ecuador
Prior art keywords
factor viii
blood coagulation
fviii
conjugated factor
conjugated
Prior art date
Application number
Other languages
English (en)
Inventor
William Henry
Original Assignee
Cantab Biopharmaceuticals Patents Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42289987&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP12012314(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cantab Biopharmaceuticals Patents Ltd filed Critical Cantab Biopharmaceuticals Patents Ltd
Publication of ECSP12012314A publication Critical patent/ECSP12012314A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención proporciona un polímero biocompatible conjugado a FVIII por medio de uno o más residuos de cisteína, adecuadamente por medio de un enlazador a través de un enlace disulfuro reducido en FVIII, y composiciones farmacéuticas que comprenden esas formas conjugadas de FVIII.
ECSP12012314 2010-04-30 2012-11-28 Factor viii conjugado para coagulación de la sangre ECSP12012314A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1007357.5A GB201007357D0 (en) 2010-04-30 2010-04-30 Conjugated factor VIII

Publications (1)

Publication Number Publication Date
ECSP12012314A true ECSP12012314A (es) 2013-05-31

Family

ID=42289987

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP12012314 ECSP12012314A (es) 2010-04-30 2012-11-28 Factor viii conjugado para coagulación de la sangre

Country Status (26)

Country Link
US (1) US20130150302A1 (es)
EP (1) EP2563402A1 (es)
JP (1) JP5870088B2 (es)
KR (1) KR20130055619A (es)
CN (1) CN102939108A (es)
AP (1) AP2012006575A0 (es)
AU (1) AU2011247147B2 (es)
BR (1) BR112012027590A2 (es)
CA (1) CA2797058A1 (es)
CL (1) CL2012003039A1 (es)
CO (1) CO6660443A2 (es)
CR (1) CR20120579A (es)
EA (1) EA201290938A1 (es)
EC (1) ECSP12012314A (es)
GB (2) GB201007357D0 (es)
IL (1) IL222566A (es)
MX (1) MX2012012683A (es)
MY (1) MY160922A (es)
NI (1) NI201200160A (es)
NZ (1) NZ603939A (es)
PE (1) PE20130254A1 (es)
PH (1) PH12012502150A1 (es)
RU (1) RU2012144555A (es)
SG (1) SG184906A1 (es)
WO (1) WO2011135307A1 (es)
ZA (1) ZA201208989B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007333049B2 (en) 2006-12-15 2014-02-20 Takeda Pharmaceutical Company Limited Factor VIIa-(poly)sialic acid conjugate having prolonged in vivo half-life
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
US8637640B2 (en) 2009-07-27 2014-01-28 Baxter International Inc. Blood coagulation protein conjugates
WO2011012850A2 (en) 2009-07-27 2011-02-03 Lipoxen Technologies Limited Glycopolysialylation of non-blood coagulation proteins
RU2744370C2 (ru) 2009-07-27 2021-03-05 Баксалта Инкорпорейтед Конъюгаты белков свертывания крови
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
PL2654794T3 (pl) 2010-12-22 2020-07-27 Baxalta GmbH Materiały i sposoby sprzęgania rozpuszczalnej w wodzie pochodnej kwasu tłuszczowego z białkiem
GB201910190D0 (en) * 2012-04-16 2019-08-28 Cantab Biopharmaceuticals Patents Ltd Optimised subsutaneous therapeutic agents
GB201417589D0 (en) 2014-10-06 2014-11-19 Cantab Biopharmaceuticals Patents Ltd Pharmaceutical Formulations
GB201518172D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for use in medicine
GB201518171D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for topical administration with therapeutic agent
GB201518170D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for subcutaneous administration with intravenous administration of therapeutic agent
KR20190086269A (ko) * 2018-01-12 2019-07-22 재단법인 목암생명과학연구소 체내 지속형 재조합 당단백질 및 이의 제조방법
WO2019219049A1 (zh) 2018-05-18 2019-11-21 北京辅仁瑞辉生物医药研究院有限公司 改进的fviii融合蛋白及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004075923A2 (en) * 2003-02-26 2004-09-10 Nektar Therapeutics Al, Corporation Polymer-factor viii moiety conjugates
GB0316294D0 (en) 2003-07-11 2003-08-13 Polytherics Ltd Conjugated biological molecules and their preparation
KR101468345B1 (ko) * 2004-11-12 2014-12-03 바이엘 헬스케어 엘엘씨 Ｆｖｉｉｉ의 부위 지향 변형
BRPI0519562A2 (pt) * 2004-12-27 2009-01-27 Baxter Int construÇço proteinÁcea, complexo, mÉtodo para prolongar a meia-vida in vivo de fator viii (fviii) ou um derivado biologicamente ativo do mesmo composiÇço farmacÊutica, e, mÉtodo para formar uma construÇço proteinÁcea
KR20080108147A (ko) * 2006-03-31 2008-12-11 백스터 인터내셔널 인코포레이티드 페질화된 인자 ｖｉｉｉ
DK2209494T3 (en) 2007-10-09 2016-10-03 Polytherics Ltd New conjugated proteins and peptides
WO2009130602A2 (en) * 2008-04-24 2009-10-29 Celtic Pharma Peg Ltd. Factor ix conjugates with extended half-lives
WO2010010324A1 (en) * 2008-07-21 2010-01-28 Polytherics Limited Novel reagents and method for conjugating biological molecules
GB0912485D0 (en) * 2009-07-17 2009-08-26 Polytherics Ltd Improved conjugation method

Also Published As

Publication number Publication date
KR20130055619A (ko) 2013-05-28
GB2492935B8 (en) 2014-10-29
US20130150302A1 (en) 2013-06-13
CO6660443A2 (es) 2013-04-30
MX2012012683A (es) 2013-04-03
PE20130254A1 (es) 2013-03-16
NI201200160A (es) 2013-04-19
GB201220667D0 (en) 2013-01-02
JP5870088B2 (ja) 2016-02-24
ZA201208989B (en) 2014-02-26
SG184906A1 (en) 2012-11-29
AU2011247147B2 (en) 2014-09-18
BR112012027590A2 (pt) 2016-08-09
PH12012502150A1 (en) 2013-02-04
CR20120579A (es) 2013-04-25
GB2492935B (en) 2014-04-30
MY160922A (en) 2017-03-31
CA2797058A1 (en) 2011-11-03
AP2012006575A0 (en) 2012-12-31
GB2492935A8 (en) 2014-10-29
HK1173946A1 (en) 2013-05-31
CN102939108A (zh) 2013-02-20
JP2013525414A (ja) 2013-06-20
IL222566A (en) 2017-12-31
GB201007357D0 (en) 2010-06-16
IL222566A0 (en) 2012-12-31
RU2012144555A (ru) 2014-06-10
CL2012003039A1 (es) 2014-01-24
AU2011247147A1 (en) 2013-01-10
EA201290938A1 (ru) 2013-04-30
WO2011135307A1 (en) 2011-11-03
GB2492935A (en) 2013-01-16
EP2563402A1 (en) 2013-03-06
NZ603939A (en) 2013-08-30

Similar Documents

Publication Publication Date Title
CR20120579A (es) Factor viii conjugado para coagulación de la sangre
ECSP12012315A (es) FACTOR VIIa CONJUGADO PARA COAGULACIÓN DE LA SANGRE
BR112012017488A2 (pt) "dispositivo"
CY1121419T1 (el) Αναστολη της φουκοσυλιωσης των πρωτεϊνων in vivo χρησιμοποιωντας αναλογα φουκοζης
CY1121560T1 (el) Ανοσογονικη συνθεση
GT201200339A (es) Compuestos, composiciones de tioacetato y mètodos de uso
CY1118680T1 (el) Φαρμακευτικη συνθεση
BRPI0917920B8 (pt) expansão direcional de dispositivos intraluminais
CY1116264T1 (el) Αντισωματα κατα ανθρωπινης αγγειοποιητινης 2
CY1121742T1 (el) Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων
CL2012002606A1 (es) Composicion farmaceutica que comprende (-)-carvona, (+)-carvona, trans-geraniol y al menos un componente elegido de aceites esenciales para uso en el tratamiento y prevencion de enfermedades virales.
BR112015015319A2 (pt) composições de nanopartícula de albumina e paclitaxel
GT201300208A (es) Novedosos derivados de azabencimidazol cíclico útiles como agentes antidiabéticos
BR112013031268A8 (pt) polipeptídeos
EP2569330A4 (en) CHLOROTOXIN VARIANTS AND CONJUGATES AND METHOD OF USE THEREOF
MX2013003365A (es) Composicion farmaceutica.
UY37922A (es) Composiciones farmacéuticas que comprenden un profármaco deadrenomedulina basado en polietilenglicol
BRPI0914410A2 (pt) composição de polidesoxirribonucleotídeo injetável para o tratamento de doenças osteoarticulares.
BR112012003800A2 (pt) composição, peptídeo, e formulação farmacêutica.
BR112014011481A2 (pt) hidrolisado de colágeno e seu uso
BR112013000779A2 (pt) composições farmacêuticas de combinação, métodos de tratamento de paciente e uso de forma potencializada ativada de anticorpo para receptor at1 de angiotensina ii e forma potencializada ativada de anticorpo para sintase no endotelial
BR112012007888A2 (pt) "métodos de tratamento usando anticorpos anti-ldl oxidada".
CY1118967T1 (el) Φαρμακευτικες συνθεσεις υψηλης δοσης βιοτινης
CO6280503A2 (es) Conjugados de neurturina novedosas para uso farmaceutico
CL2009000904A1 (es) Compuestos derivados de ciclohexil sulfonamidas que tienen actividad antagonista en el receptor npy y5, composicion farmaceutica y formulacion farmaceutica que los comprende.